193 related articles for article (PubMed ID: 22099706)
1. The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives.
Schlesinger M; Schmitz P; Zeisig R; Naggi A; Torri G; Casu B; Bendas G
Thromb Res; 2012 May; 129(5):603-10. PubMed ID: 22099706
[TBL] [Abstract][Full Text] [Related]
2. Binding between heparin and the integrin VLA-4.
Schlesinger M; Simonis D; Schmitz P; Fritzsche J; Bendas G
Thromb Haemost; 2009 Nov; 102(5):816-22. PubMed ID: 19888514
[TBL] [Abstract][Full Text] [Related]
3. Cyr61 is a target for heparin in reducing MV3 melanoma cell adhesion and migration via the integrin VLA-4.
Schmitz P; Gerber U; Schütze N; Jüngel E; Blaheta R; Naggi A; Torri G; Bendas G
Thromb Haemost; 2013 Nov; 110(5):1046-54. PubMed ID: 24009013
[TBL] [Abstract][Full Text] [Related]
4. The role of VLA-4 binding for experimental melanoma metastasis and its inhibition by heparin.
Schlesinger M; Roblek M; Ortmann K; Naggi A; Torri G; Borsig L; Bendas G
Thromb Res; 2014 May; 133(5):855-62. PubMed ID: 24636486
[TBL] [Abstract][Full Text] [Related]
5. Melanoma cell adhesion can be blocked by heparin in vitro: suggestion of VLA-4 as a novel target for antimetastatic approaches.
Fritzsche J; Simonis D; Bendas G
Thromb Haemost; 2008 Dec; 100(6):1166-75. PubMed ID: 19132244
[TBL] [Abstract][Full Text] [Related]
6. Latent heparanase facilitates VLA-4-mediated melanoma cell binding and emerges as a relevant target of heparin in the interference with metastatic progression.
Gerber U; Hoß SG; Shteingauz A; Jüngel E; Jakubzig B; Ilan N; Blaheta R; Schlesinger M; Vlodavsky I; Bendas G
Semin Thromb Hemost; 2015 Mar; 41(2):244-54. PubMed ID: 25682080
[TBL] [Abstract][Full Text] [Related]
7. High affinity interaction of integrin alpha4beta1 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers.
Klemke M; Weschenfelder T; Konstandin MH; Samstag Y
J Cell Physiol; 2007 Aug; 212(2):368-74. PubMed ID: 17352405
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Tumor-Host Cell Interactions Using Synthetic Heparin Mimetics.
Gockel LM; Heyes M; Li H; Al Nahain A; Gorzelanny C; Schlesinger M; Holdenrieder S; Li JP; Ferro V; Bendas G
ACS Appl Mater Interfaces; 2021 Feb; 13(6):7080-7093. PubMed ID: 33533245
[TBL] [Abstract][Full Text] [Related]
9. Blocking of integrin-mediated human MV3 melanoma cell binding by commercial and modified heparins.
Schlesinger M; Naggi A; Torri G; Zeisig R; Alexander M; Schmitz P; Casu B; Bendas G
Int J Clin Pharmacol Ther; 2010 Jul; 48(7):448-50. PubMed ID: 20557840
[No Abstract] [Full Text] [Related]
10. Selectively desulfated heparin inhibits P-selectin-mediated adhesion of human melanoma cells.
Wei M; Gao Y; Tian M; Li N; Hao S; Zeng X
Cancer Lett; 2005 Nov; 229(1):123-6. PubMed ID: 16157224
[TBL] [Abstract][Full Text] [Related]
11. Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity.
Stevenson JL; Choi SH; Varki A
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7003-11. PubMed ID: 16203794
[TBL] [Abstract][Full Text] [Related]
12. In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma.
Gandoglia I; Ivaldi F; Carrega P; Armentani E; Ferlazzo G; Mancardi G; Kerlero de Rosbo N; Uccelli A; Laroni A
Immunol Lett; 2017 Jan; 181():109-115. PubMed ID: 27919749
[TBL] [Abstract][Full Text] [Related]
13. Low molecular weight heparin inhibits sickle erythrocyte adhesion to VCAM-1 through VLA-4 blockade in a standardized microfluidic flow adhesion assay.
Lancelot M; White J; Sarnaik S; Hines P
Br J Haematol; 2017 Aug; 178(3):479-481. PubMed ID: 27341635
[No Abstract] [Full Text] [Related]
14. Inhibitory effect of non-anticoagulant heparin (S-NACH) on pancreatic cancer cell adhesion and metastasis in human umbilical cord vessel segment and in mouse model.
Sudha T; Phillips P; Kanaan C; Linhardt RJ; Borsig L; Mousa SA
Clin Exp Metastasis; 2012 Jun; 29(5):431-9. PubMed ID: 22415710
[TBL] [Abstract][Full Text] [Related]
15. Modified heparins inhibit integrin alpha(IIb)beta(3) mediated adhesion of melanoma cells to platelets in vitro and in vivo.
Zhang C; Liu Y; Gao Y; Shen J; Zheng S; Wei M; Zeng X
Int J Cancer; 2009 Nov; 125(9):2058-65. PubMed ID: 19598263
[TBL] [Abstract][Full Text] [Related]
16. Integrin VLA-4 enhances sialyl-Lewisx/a-negative melanoma adhesion to and extravasation through the endothelium under low flow conditions.
Liang S; Dong C
Am J Physiol Cell Physiol; 2008 Sep; 295(3):C701-7. PubMed ID: 18632734
[TBL] [Abstract][Full Text] [Related]
17. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo.
Ludwig RJ; Alban S; Bistrian R; Boehncke WH; Kaufmann R; Henschler R; Gille J
Thromb Haemost; 2006 Mar; 95(3):535-40. PubMed ID: 16525583
[TBL] [Abstract][Full Text] [Related]
18. Stepwise inhibition of T cell recruitment at post-capillary venules by orally active desulfated heparins in inflammatory arthritis.
Al Faruque H; Kang JH; Hwang SR; Sung S; Alam MM; Sa KH; Nam EJ; Byun YR; Kang YM
PLoS One; 2017; 12(4):e0176110. PubMed ID: 28419144
[TBL] [Abstract][Full Text] [Related]
19. Relationship between molecular and cellular dissociation rates for VLA-4/VCAM-1 interaction in the absence of shear stress.
Zwartz G; Chigaev A; Foutz T; Larson RS; Posner R; Sklar LA
Biophys J; 2004 Feb; 86(2):1243-52. PubMed ID: 14747358
[TBL] [Abstract][Full Text] [Related]
20. The mechanism of melanoma-associated thrombin activity and von Willebrand factor release from endothelial cells.
Kerk N; Strozyk EA; Pöppelmann B; Schneider SW
J Invest Dermatol; 2010 Sep; 130(9):2259-68. PubMed ID: 20505748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
